Financials data is unavailable for this security.
Cash flow in CNYView more
In 2023, Wuhan YZY Biopharma Co Ltd increased its cash reserves by 28.12%, or 43.16m. Cash Flow from Financing totalled 176.29m or -- of revenues. In addition the company used 186.02m for operations while cash from investing totalled 54.81m.
Cash flow per share | -0.9995 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.277 |
---|---|
Tangible book value per share | 0.277 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.24 |
---|---|
Quick ratio | 1.21 |
Total debt/total equity | 2.42 |
---|---|
Total debt/total capital | 0.7078 |
More ▼